Infliximab-associated reversible cholestatic liver disease

Infliximab, a novel therapy for Crohn disease, has been shown to be both sa fe and effective. We describe a 44-year-old woman with Crohn disease who de veloped jaundice after an infusion of infliximab, Multiple investigations w ere undertaken, cholestatic liver disease was diagnosed, and her condition improved with supportive therapy. Although likely a rare adverse event, cho lestatic liver injury should be considered in patients presenting with jaun dice who have received infliximab therapy.